

Research Article

Relationship between Particulate Matter (PM₁₀) and Airway Inflammation Measured with Exhaled Nitric Oxide Test in Seoul, Korea

Juwhan Choi ¹, Jae Kyeom Sim,¹ Jee Youn Oh,¹ Young Seok Lee,¹ Gyu Young Hur,¹ Sung Yong Lee,¹ Jae Jeong Shim,¹ Ji-yong Moon ², and Kyung Hoon Min ¹

¹Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea

²Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Gyeongchun-ro 153, Guri-si, Gyeonggi-do 11923, Republic of Korea

Correspondence should be addressed to Ji-yong Moon; moonji@hanyang.ac.kr and Kyung Hoon Min; minkyunghoon@korea.ac.kr

Received 5 January 2020; Revised 6 February 2020; Accepted 18 February 2020; Published 17 March 2020

Academic Editor: Andrea S. Melani

Copyright © 2020 Juwhan Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Particulate matter (PM) is increasing every year in Asia. It is not fully understood how the airway is affected when inhaling PM. We investigated the correlation between particulate matter with a diameter of less than 10 μm (PM₁₀) and fractional exhaled nitric oxide (FeNO) to determine whether PM causes airway inflammation. **Material and Methods.** We analyzed patients who visited our outpatient clinic and tested FeNO from January 2016 to December 2017 at the Korea University Guro Hospital. PM₁₀ data were provided by the government of the Republic of South Korea, and measuring station of PM₁₀ is located 800 meters from the hospital. We analyzed the correlation between PM₁₀ and FeNO by a Pearson correlation analysis and by a multivariate linear regression analysis. To identify the most correlated times, we analyzed the correlation between the FeNO and PM₁₀ daily average from the day of visit to 4 days before visit. **Results.** FeNO positively correlated with PM₁₀ at two days before hospital visit in the Pearson correlation (Pearson correlation coefficient = 0.057; *P*-value = 0.023) and in the multivariate linear regression analysis (*B* = 0.051, *P*-value = 0.026). If the PM₁₀ increased by 100 $\mu\text{g}/\text{m}^3$, the FeNO result was expected to rise to 8.3 ppb in healthy people without respiratory disease. **Conclusion.** The positive correlation was found in both healthy people and asthmatic patients. Therefore, PM₁₀ can increase airway inflammation.

1. Introduction

Particulate matter (PM) is a global environmental issue [1]. Recently, PM is increasing every year in China and in neighboring countries [2]. Particularly in Korea, outdoor activities are increasingly difficult and quality of life is diminishing from PM [3]. The higher the PM levels, the more people complain of various respiratory symptoms, and even those who do not have respiratory diseases need medical treatment reducing respiratory symptoms [4].

Generally, PM is known to cause abnormal inflammatory and coagulation responses in the entire body [5, 6].

And, PM can act as a direct irritant to the airway and causes respiratory disease. Incidences of airway disease and the frequency of acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are increasing [7]. In addition, incidences of lung cancer are also expected to increase [8]. However, it is not fully understood how the airway reacts when inhaling PM. In addition, there is a lack of research on the adverse effects of PM in healthy people without respiratory disease.

Among the known respiratory tests, fractional exhaled nitric oxide (FeNO) is one that is a marker of airway inflammation [9]. FeNO is useful because it is noninvasive and

can be easily examined in an outpatient clinic. When treating asthma and COPD, FeNO can predict airway inflammation and is also used to predict inhaled corticosteroid (ICS) responses [10]. Therefore, we investigated the correlation between PM and FeNO to determine whether PM causes airway inflammation.

2. Materials and Methods

2.1. Data Collection. We obtained FeNO results from January 2016 to December 2017 at the Korea University Guro Hospital by searching the hospital's electronic records. FeNO was measured using the nitric oxide delivery system monitor approved by the US Food and Drug Administration (NIOX MINO, Aerocrine, Sweden). We asked subjects about drugs used which could affect FeNO result at the time of the test. We instruct subjects to avoid exercise, smoking, and caffeine ingestion within 1 hour of FeNO test. This study was approved by the Institutional Review Board of the Korea University Guro Hospital (approval number: K2018-0377-001). Since our study was retrospective, patient consent was not necessary, and we maintained patient confidentiality.

We collected and analyzed the following medical records: age, gender, history of respiratory disease, pulmonary related treatment before the outpatient clinic visit, and the pulmonary function test (PFT).

We used particulate matter with a diameter of less than $10\ \mu\text{m}$ (PM_{10}) as the representative value. PM_{10} data were provided by the government of the Republic of South Korea. PM_{10} data were obtained from a government measuring station located 800 meters from the Korea University Guro Hospital. And humidity and temperature data were also provided by the government of the Republic of South Korea.

2.2. Subjects. We included patients who visited our outpatient clinic for the first time and those who visited periodically due to asthma, allergic rhinitis, and COPD. Asthma was diagnosed based on the Global Initiative for Asthma (GINA) guidelines (patients showed positive for the bronchodilator reversibility test, positive for the bronchial challenge test, or positive for the exercise challenge test) [11]. Allergic rhinitis was diagnosed based on the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline (patients had a typical history of allergic symptoms, such as rhinorrhea, sneezing, sneezing, nasal obstruction, and pruritus and diagnostic tests such as allergen-specific immunoglobulin E in the skin or blood specific immunoglobulin E) [12]. COPD was diagnosed based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (PFT showed an obstructive pattern with a ratio of forced expiratory volume in the first second (FEV1) to forced vital capacity (FVC) of less than 70% in post bronchodilator spirometry) [13].

Patients were excluded if they (1) had a comorbidity that could limit daily life, such as cancer, myocardial infarction, brain hemorrhage, and brain infarction, (2) were chronically taking oral steroids or immunosuppressive drugs because of rheumatology disease or organ transplants, (3) were taking

antibiotics due to an acute infection, (4) if they did not do PFT, or (5) if FeNO was performed during hospitalization.

2.3. Statistical Analysis. Data were analyzed using SPSS 20 software (SPSS for Windows, IBM Corporation, Armonk, NY, USA). Data were presented as average \pm standard deviation (SD). The correlation coefficients between FeNO and PM_{10} were analyzed by a Pearson correlation analysis. To identify the most correlated times, we analyzed the correlation between FeNO and PM_{10} daily averages from the day of visit to 4 days before visit. All FeNO tests were performed on the day of the outpatient visit. In addition, we performed a multivariate linear regression analysis that included various factors affecting FeNO. We adjusted patient age, sex, history of respiratory disease, pulmonary related treatments before the visit, humidity, and temperature in a multivariate analysis. In the multivariate analysis, B was the regression coefficient, and the positive sign of the regression coefficient meant that the variables were positively associated. The trend lines were obtained by a linear model, using the equation $Y = b_0 + (b_1 \times t)$. " b_1 " is a slope of the regression line, and " b_0 " is an intercept of the regression line with the Y-axis. An additional sub-analysis was conducted by dividing the group according to history of respiratory disease and pulmonary related treatment. In our sub-analysis, "no history of respiratory disease" was defined as the group without asthma, COPD, allergic rhinitis, and no obstructive or restrictive pattern on the PFT. And, "no pulmonary medication" was defined as the group that did not use any medication or inhaler. P values less than 0.05 were defined as statistically significant.

3. Results and Discussion

3.1. Baseline Characteristic. According to the exclusion criteria, 1,574 FeNO results and 1,439 patients were included (Table 1). The average age was 48.3 ± 16.1 years. Men were 43.7 percent and women 56.3 percent of the patients. The asthma patients were 23.3 percent, the allergic rhinitis patients were 15.4 percent, and the COPD patients were 3.0 percent. 19.3 percent of events were using one or more pulmonary-related medications. 70.5 percent of events showed normal PFT findings. And the average value of PM_{10} was $47.3 \pm 25.2\ \mu\text{g}/\text{m}^3$, and the average value of FeNO was 31.9 ± 30.8 ppb.

3.2. Correlation between PM_{10} and FeNO. In the Pearson correlation, FeNO positively correlated with PM_{10} at the day of the hospital visit (Pearson correlation coefficient = 0.061; P value = 0.016). And, FeNO also positively correlated with PM_{10} at two days before hospital visit (Pearson correlation coefficient = 0.057; P value = 0.023) (Figure 1(a)). There were no statistically significant correlations with other days. In the multivariate linear regression analysis, there was a positive correlation between FeNO and PM_{10} , which was measured two days before the hospital visit ($B = 0.051$, P value = 0.026). If the PM_{10} increased by $100\ \mu\text{g}/\text{m}^3$, the FeNO value was expected to rise to 5.1 ppb. And, there was no statistically

TABLE 1: Baseline characteristics.

	Events
No. of outpatient clinic visits/patients	1,574/1,439
Age (years)*	48.3 ± 16.1
Gender	
Male [†]	688 (43.7%)
Female [†]	886 (56.3%)
History of respiratory disease	
Asthma [†]	367 (23.3%)
Chronic obstructive pulmonary disease [†]	48 (3.0%)
Allergic rhinitis [†]	242 (15.4%)
Pulmonary-related medication before the visit	
INS [†]	82 (5.2%)
ICS [†]	204 (13.0%)
LABA or LAMA [†]	201 (12.8%)
LTRA [†]	153 (9.7%)
Antihistamine [†]	187 (11.9%)
Base-line spirometry after bronchodilation	
FEV1 (liters)*	2.8 ± 0.8
FEV1 (% of predicted value)*	87.5 ± 14.6
FVC (liters)*	3.5 ± 1.0
FVC (% of predicted value)*	90.1 ± 12.9
Ratio of FEV1 to FVC (%)*	77.9 ± 10.1
Bronchodilator response (positive) [†]	273 (17.3%)
Asthma provocation test (positive) [†]	105 (6.7%)

INS, intranasal corticosteroids; ICS, inhaled corticosteroid; LABA, long-acting B agonist bronchodilator; LAMA, long-acting antimuscarinic agent bronchodilator; LTRA, leukotriene receptor antagonist; FEV1, forced expiratory volume in one second; FVC, forced vital capacity. *Numbers are presented as average ± standard deviation. †Numbers are presented as *n* (%).

significant correlation with other days, including PM₁₀ at the day of hospital visit (Table 2).

3.3. Subgroup Analysis. We performed the subgroup analysis according to the patient's history of respiratory disease and the pulmonary-related medication before the visit. And, the PM₁₀ value two days before the hospital visit was used as the reference value because it was statistically significant in the multivariate analysis. PM₁₀ results were similar among the subgroups. FeNO values were highest in the asthma group and lowest in the "no history of respiratory disease" group. In the Pearson correlation, the asthma group (Pearson correlation coefficient = 0.104; *P* value = 0.047), the "no history of respiratory disease" group (Pearson correlation coefficient = 0.081; *P* value = 0.030) and the "no pulmonary medication" group (Pearson correlation coefficient = 0.070; *P* value = 0.012) showed a positive correlation with FeNO (Figures 1(b)–1(d)). In the multivariate linear regression analysis, there was a positive correlation between FeNO and PM₁₀ in the "no history of respiratory disease" group (*B* = 0.083, *P* value = 0.024) and the "no pulmonary medication" group (*B* = 0.053, *P* value = 0.035). And, there was no statistically significant correlation with the other groups, including the asthma group (Table 3).

4. Discussion

This study is the first to demonstrate the correlation between PM₁₀ and FeNO in Korea. A total of 1,574 events were

included, and various factors that could affect FeNO were investigated. In addition to a univariate analysis, we performed a multivariate analysis to adjust various factors that could affect FeNO. Through the subgroup analysis, we confirmed the same results under various conditions. As such, we confirmed a positive correlation between PM₁₀ and FeNO.

PM is generated from automobile exhaust and from construction and various industries, and it is a complex containing heavy metals and toxic chemicals. It is generally known that PM is composed of sulfate, nitrate, carbon, and black dust. PM₁₀ means a PM with a diameter of less than 10 μm, which is about one-fifth of that of human hair. PM stays in the atmosphere and is absorbed into the body through the skin, eyes, and the part of the respiratory tract exposed to the outside [14, 15]. PM can act as an irritant or allergen at the primary contact site and causes local adverse effects. In addition, PM causes abnormal inflammation and anticoagulation in the body [16, 17]. The airway, which is the primary exposed organ, is considered to have higher adverse effects from PM than other organs [18]. Even in healthy people, exposure to PM can lead to abnormal inflammatory responses in the airways.

PM is associated with the development and aggravation of respiratory diseases, such as asthma and COPD. In addition to the respiratory system, PM can cause disease in all organs of the body, including myocardial infarction, brain stroke, atopic dermatitis, and allergic rhinitis. On high PM days, healthy people also complain of nonspecific symptoms, such as runny nose, sputum, cough, and itching. Most of the PM-related studies so far have primarily focused on patients, but studies are also needed to analyze its effects on healthy people.

Nitric oxide (NO) is a biological mediator produced in human lungs [19]. The NO produced in the lungs is released outside during exhalation [20, 21]. NO is known to act as a vasodilator, bronchodilator, neurotransmitter, and inflammatory mediator in the airway [22–24]. Recently, NO was recognized as an important key to understanding lung biology and the pathophysiology of airway diseases. When inflammation occurs in the airway, nitric oxide synthase is upregulated and NO is generated in airway epithelial cells [25, 26]. The FeNO test has been increasingly used because it can easily and noninvasively measure NO. FeNO is also known to be associated with various interleukins, cytokines, and sputum eosinophilia [27, 28]. Therefore, FeNO is considered a test reflecting airway inflammation and airway hyperresponsiveness [29–31].

FeNO has a broad clinical use. The National Institute for Health and Care Excellence (NICE) guideline says that FeNO can be used for asthma diagnosis [32]. Other researches recommend that FeNO is useful as a reference for diagnosing asthma [33]. In particular, FeNO is more useful for young children who have difficulty performing PFT [34]. Some studies suggest that FeNO is also useful for screening high-risk groups for asthma [35]. FeNO is also useful for predicting ICS response [36]. Currently, medication control is symptom dependent for the treatment of asthma. FeNO can be used as an objective indicator for medication control [37].




FIGURE 1: Trend line according to PM_{10} and FeNO. (a) All. (b) Asthma. (c) No history of respiratory disease. (d) No pulmonary medication. PM_{10} values were based on two days before hospital visit. PM_{10} , particulate matter with a diameter of less than $10\ \mu\text{m}$; FeNO, fractional exhaled nitric oxide.

TABLE 2: Correlation analysis of PM_{10} and FeNO by the Pearson correlation and multivariate linear regression analysis (most correlated time).

PM_{10} measurement date	PM_{10} day average*	Univariate		Multivariate	
		Correlation coefficient	<i>P</i> value	<i>B</i>	<i>P</i> value
The day of hospital visit	45.88 ± 20.24	0.061	0.016	0.043	0.064
One day before hospital visit	45.74 ± 21.22	0.046	0.067	0.034	0.145
Two days before hospital visit	47.33 ± 25.20	0.057	0.023	0.051	0.026
Three days before hospital visit	47.68 ± 25.06	0.049	0.053	0.040	0.083
Four days before hospital visit	47.88 ± 23.34	0.025	0.312	0.023	0.325

PM_{10} , particulate matter with a diameter of less than $10\ \mu\text{m}$; FeNO, fractional exhaled nitric oxide. *B* is the regression coefficient, and the positive sign of regression coefficient means that the variables are positively associated. The multivariate linear regression analysis is adjusted for age, sex, previous history of respiratory disease (asthma, allergic rhinitis, and chronic obstructive pulmonary disease), pulmonary-related medication before the visit (antihistamine, intranasal corticosteroids, inhaled corticosteroids, and leukotriene receptor antagonist), humidity, and temperature. *Numbers are presented as the average \pm standard deviation.

TABLE 3: Correlation analysis of PM₁₀ and FeNO by the Pearson correlation and multivariate linear regression analysis according to subgroup.

Subgroup	Number of events	FeNO* (ppb)	PM ₁₀ * (µg/m ³)	Univariate		Multivariate	
				Correlation coefficient	P value	B	P value
History of respiratory disease							
Asthma [†]	367	52.3 ± 43.8	48.0 ± 25.7	0.104	0.047	0.093	0.072
Allergic rhinitis [†]	242	44.1 ± 37.0	47.8 ± 24.9	0.091	0.160	0.096	0.128
Chronic obstructive pulmonary disease [†]	48	33.9 ± 44.8	47.9 ± 22.7	-0.036	0.807	-0.058	0.708
No history of respiratory disease [†]	715	23.2 ± 19.8	47.5 ± 25.7	0.081	0.030	0.083	0.024
Pulmonary-related medication before the visit							
Pulmonary medication [‡]	309	36.3 ± 29.5	46.7 ± 21.2	-0.05	0.926	0.013	0.814
No pulmonary medication [‡]	1265	30.8 ± 31.1	47.5 ± 26.1	0.070	0.012	0.053	0.035

PM₁₀, particulate matter with a diameter of less than 10 µm; FeNO, fractional exhaled nitric oxide. *B* is the regression coefficient, and the positive sign of regression coefficient means that the variables are positively associated. PM₁₀ values were based on two days before the hospital visit. *Numbers are presented as mean ± standard deviation. †Multivariate linear regression analysis is adjusted for age, sex, pulmonary-related medication before the visit (antihistamine, intranasal corticosteroids, inhaled corticosteroids, and leukotriene receptor antagonist), humidity, and temperature. ‡Multivariate linear regression analysis is adjusted for age, sex, previous history of respiratory disease (asthma, allergic rhinitis, and chronic obstructive pulmonary disease), humidity, and temperature.

Few studies have focused on the correlation between FeNO and PM [38]. Most of the previous studies were small cases or were limited to children [39]. In addition, most of the studies were conducted on asthma patients [40]. Our study was the first to include a large number of patients and healthy people.

Our research had some limitations. First, we did not adjust the height, weight, smoking history, nitric oxide, diet, house air quality, seasonality, and weather conditions in the multivariate analysis. FeNO is affected by various factors, for example, drugs, history of respiratory disease, gender, age, height, weight, smoking history, and nitric oxide level in atmosphere. Data on height, weight, and smoking history were not accurate and could not be analyzed. But, regarding seasonality and weather conditions, we included humidity and temperature. Secondly, the degree of exposure of PM may be slightly different. The degree of exposure may vary depending on the level of activity and location. To compensate for this, we excluded inpatients. Also, we excluded patients with diseases in which physical activity could be limited. Third, the differences in medication dosages and compliance were not corrected. In cases of patients with antihistamines, ICS, and intranasal corticosteroids, there were those with differences in the components and dosages of the drugs. There may also be differences in the proficiency and compliance with the inhaler. Fourth, we did not have big data from repeated comparisons of the same person. If repeated tests were to be conducted on the same person, a more stringent comparison would be possible. In our study, 115 subjects were repeatedly examined. A positive correlation was also observed in the repeated test group. Fifth, our study design and statistical analysis are very simple, so there are a lot of confounding variables. To overcome this limitation, we included a large number of subjects. In addition, many factors were included in the meta-analysis.

5. Conclusions

We confirmed a positive correlation between PM₁₀ and FeNO. Therefore, PM₁₀ may cause airway inflammation. The

same results were obtained in healthy persons as well as patients with respiratory conditions. Even healthy people may develop airway inflammation and respiratory symptoms caused by PM₁₀. In addition, it should be considered that PM₁₀ affects the FeNO value on days with very high PM₁₀ value.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Some of the results of this study have been previously reported in the form of an abstract in the 23rd Congress of the Asian Pacific Society of Respiriology.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Ji-yong Moon and Kyung Hoon Min contributed equally to this work.

Acknowledgments

This study was supported by a grant from Korea University, Seoul, Korea (O1903991).

References

- [1] W. Du, X. Li, Y. Chen, and G. Shen, "Household air pollution and personal exposure to air pollutants in rural China—a review," *Environmental Pollution*, vol. 237, pp. 625–638, 2018.
- [2] S. Liu, M. Zhou, L. Wang et al., "Burden of disease attributable to ambient particulate matter pollution in 1990 and 2010 in China," *Zhonghua Yu Fang Yi Xue Za Zhi*, vol. 49, no. 4, pp. 327–333, 2015.

- [3] S. Steinle, S. Reis, C. E. Sabel et al., "Personal exposure monitoring of PM 2.5 in indoor and outdoor microenvironments," *Science of The Total Environment*, vol. 508, pp. 383–394, 2015.
- [4] E. Nkhama, M. Ndhlovu, J. Dvonch et al., "Effects of airborne particulate matter on respiratory health in a community near a cement factory in Chilanga, Zambia: results from a panel study," *International Journal of Environmental Research and Public Health*, vol. 14, no. 11, p. 1351, 2017.
- [5] A. Dabass, E. O. Talbott, J. R. Rager et al., "Systemic inflammatory markers associated with cardiovascular disease and acute and chronic exposure to fine particulate matter air pollution (PM2.5) among US NHANES adults with metabolic syndrome," *Environmental Research*, vol. 161, pp. 485–491, 2018.
- [6] R. Chen, H. Li, J. Cai et al., "Fine particulate air pollution and the expression of microRNAs and circulating cytokines relevant to inflammation, coagulation, and vasoconstriction," *Environmental Health Perspectives*, vol. 126, no. 1, Article ID 17007, 2018.
- [7] I. Stevanovic, M. Jovasevic-Stojanovic, and J. Stosic, "Association between ambient air pollution, meteorological conditions and exacerbations of asthma and chronic obstructive pulmonary disease in adult citizens of the town of Smederevo," *Vojnosanitetski Pregled*, vol. 73, no. 2, pp. 152–158, 2016.
- [8] P. Cui, Y. Huang, J. Han, F. Song, and K. Chen, "Ambient particulate matter and lung cancer incidence and mortality: a meta-analysis of prospective studies," *European Journal of Public Health*, vol. 25, no. 2, pp. 324–329, 2015.
- [9] T. Shimoda, Y. Obase, Y. Nagasaka, H. Nakano, R. Kishikawa, and T. Iwanaga, "Airway inflammation phenotype prediction in asthma patients using lung sound analysis with fractional exhaled nitric oxide," *Allergology International*, vol. 66, no. 4, pp. 581–585, 2017.
- [10] M. Llunor, P. Barranco, E.-D. Amaya et al., "Relationship between upper airway diseases, exhaled nitric oxide, and bronchial hyperresponsiveness to methacholine," *Journal of Asthma*, vol. 56, no. 1, pp. 53–60, 2019.
- [11] F. Horak, D. Doberer, E. Eber et al., "Diagnosis and management of asthma—statement on the 2015 GINA guidelines," *Wiener Klinische Wochenschrift*, vol. 128, no. 15–16, pp. 541–554, 2016.
- [12] J. L. Brożek, J. Bousquet, I. Agache et al., "Allergic rhinitis and its Impact on asthma (ARIA) guidelines-2016 revision," *Journal of Allergy and Clinical Immunology*, vol. 140, no. 4, pp. 950–958, 2017.
- [13] C. F. Vogelmeier, G. J. Criner, F. J. Martinez et al., "Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary," *Archivos de Bronconeumología (English Edition)*, vol. 53, no. 3, pp. 128–149, 2017.
- [14] M. Watanabe, H. Noma, J. Kurai et al., "Association of short-term exposure to ambient fine particulate matter with skin symptoms in schoolchildren: a panel study in a rural area of western Japan," *International Journal of Environmental Research and Public Health*, vol. 14, no. 3, p. 299, 2017.
- [15] Y.-H. Cui, Z.-X. Hu, Z.-X. Gao et al., "Airborne particulate matter impairs corneal epithelial cells migration via disturbing FAK/RhoA signaling pathway and cytoskeleton organization," *Nanotoxicology*, vol. 12, no. 4, pp. 312–324, 2018.
- [16] X. Xu, A. Qimuge, H. Wang et al., "IRE1 α /XBP1s branch of UPR links HIF1 α activation to mediate ANGII-dependent endothelial dysfunction under particulate matter (PM) 2.5 exposure," *Scientific Reports*, vol. 7, no. 1, p. 13507, 2017.
- [17] L. Cantone, S. Iodice, L. Tarantini et al., "Particulate matter exposure is associated with inflammatory gene methylation in obese subjects," *Environmental Research*, vol. 152, pp. 478–484, 2017.
- [18] G. C. Khilnani and P. Tiwari, "Air pollution in India and related adverse respiratory health effects," *Current Opinion in Pulmonary Medicine*, vol. 24, no. 2, pp. 108–116, 2018.
- [19] S. Ewald-Kleimeier, A. Lotz, R. Merget, T. Brüning, and O. Hagemeyer, "Exhaled nitric oxide in specific inhalation challenge," *Neurobiology of Respiration*, vol. 788, pp. 255–264, 2013.
- [20] C. Lane, D. Knight, S. Burgess et al., "Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath," *Thorax*, vol. 59, no. 9, pp. 757–760, 2004.
- [21] J. Jiang, N. Malavia, V. Suresh, and S. C. George, "Nitric oxide gas phase release in human small airway epithelial cells," *Respiratory Research*, vol. 10, no. 1, p. 3, 2009.
- [22] Y. H. Kim, I. S. Sol, S. H. Yoon et al., "Association of extended nitric oxide parameters with bronchial hyperresponsiveness and bronchodilator response in children with asthma," *Journal of Breath Research*, vol. 11, no. 4, Article ID 046003, 2017.
- [23] G. G. Konduri, A. J. Afolayan, A. Eis, K. A. Pritchard Jr., and R.-J. Teng, "Interaction of endothelial nitric oxide synthase with mitochondria regulates oxidative stress and function in fetal pulmonary artery endothelial cells," *American Journal of Physiology-Lung Cellular and Molecular Physiology*, vol. 309, no. 9, pp. L1009–L1017, 2015.
- [24] B. J. Hsia, A. M. Pastva, and C. D. Giamberardino, "Increased nitric oxide production prevents airway hyperresponsiveness in caveolin-1 deficient mice following endotoxin exposure," *Journal of Allergy & Therapy*, vol. 1, no. 1, 2012.
- [25] A. B. Roos, M. Mori, R. Grönneberg et al., "Elevated exhaled nitric oxide in allergen-provoked asthma is associated with airway epithelial iNOS," *PLoS One*, vol. 9, no. 2, Article ID e90018, 2014.
- [26] M. W. Foster, J. W. Thompson, M. T. Forrester et al., "Proteomic analysis of the NOS₂ interactome in human airway epithelial cells," *Nitric Oxide*, vol. 34, pp. 37–46, 2013.
- [27] J. Gao, M. Zhang, L. Zhou et al., "Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD," *International Journal of Chronic Obstructive Pulmonary Disease*, vol. 12, pp. 1287–1293, 2017.
- [28] S. Agrawal and R. G. Townley, "Role of periostin, FeNO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma," *Expert Opinion on Biological Therapy*, vol. 14, no. 2, pp. 165–181, 2014.
- [29] M. Fukuhara, T. Tsuburai, Y. Nakamura et al., "The fraction of exhaled nitric oxide (FeNO) and forced oscillation technique (FOT) can predict bronchial hyperresponsiveness against acetylcholine in treated asthmatics," *Arerugi*, vol. 66, no. 1, pp. 42–49, 2017.
- [30] P. E. Silkoff, M. Laviolette, D. Singh et al., "Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients," *Journal of Allergy and Clinical Immunology*, vol. 140, no. 3, pp. 710–719, 2017.
- [31] H. Coumou and E. H. Bel, "Improving the diagnosis of eosinophilic asthma," *Expert Review of Respiratory Medicine*, vol. 10, no. 10, pp. 1093–1103, 2016.
- [32] National Institute for Health and Care Excellence, *Asthma: Diagnosis and Monitoring of Asthma in Adults, Children and Young People*, National Institute for Health and Care Excellence, London, UK, 2017, <https://www.nice.org.uk/guidance/ng80/evidence/full-guideline-asthma-diagnosis-and-monitoring-pdf-4656178047>.

- [33] S. Karrasch, K. Linde, G. Rücker et al., “Accuracy of FeNO for diagnosing asthma: a systematic review,” *Thorax*, vol. 72, no. 2, pp. 109–116, 2017.
- [34] L. P. Malmberg, A. S. Pelkonen, T. Haahtela, and M. Turpeinen, “Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma,” *Thorax*, vol. 58, no. 6, pp. 494–499, 2003.
- [35] K. Alving, “FeNO and suspected asthma: better to identify responsiveness to treatment than to label with a diagnosis,” *The Lancet Respiratory Medicine*, vol. 6, no. 1, pp. 3–5, 2018.
- [36] D. B. Price, R. Buhl, A. Chan et al., “Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial,” *The Lancet Respiratory Medicine*, vol. 6, no. 1, pp. 29–39, 2018.
- [37] A. D. Smith, J. O. Cowan, K. P. Brassett, G. P. Herbison, and D. R. Taylor, “Use of exhaled nitric oxide measurements to guide treatment in chronic asthma,” *New England Journal of Medicine*, vol. 352, no. 21, pp. 2163–2173, 2005.
- [38] J. Y. Kim, R. Hauser, M. P. Wand, R. F. Herrick, C. J. Amarasiriwardena, and D. C. Christiani, “The association of expired nitric oxide with occupational particulate metal exposure,” *Environmental Research*, vol. 93, no. 2, pp. 158–166, 2003.
- [39] A. Neisi, M. Vosoughi, E. Idani et al., “Comparison of normal and dusty day impacts on fractional exhaled nitric oxide and lung function in healthy children in Ahvaz, Iran,” *Environmental Science and Pollution Research*, vol. 24, no. 13, pp. 12360–12371, 2017.
- [40] C. L. Maikawa, S. Weichenthal, A. J. Wheeler et al., “Particulate oxidative burden as a predictor of exhaled nitric oxide in children with asthma,” *Environmental Health Perspectives*, vol. 124, no. 10, pp. 1616–1622, 2016.